

AMENDMENTS TO THE CLAIMS

A complete listing of all claims is presented below with insertions underlined (e.g., insertion), and deletions strikethrough or in double brackets (e.g., ~~deletion~~ or ~~[[deletion]]~~):

1.-13. (Cancelled)

14. (Currently Amended) A prosthesis for placement at an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen;

at least one frond two elongate, flexible fronds each having a first end, a second end and a length in between, the fronds extending from an end of the support and configured to be positioned across the Os and into the main body lumen; and

at least one circumferential link connected to the second ends of the fronds, the circumferential link spaced axially apart from the support by the fronds;

the elongate, flexible fronds, the support and the circumferential link defining a unitary body as deployed, having elongate side wall openings in between adjacent fronds for facilitating crossing of a main vessel stent therethrough when the support is positioned in the branch body lumen and the circumferential link is positioned in the main body lumen.

15. (Currently Amended) The prosthesis as in Claim 14, wherein the circumferential link comprises an undulating pattern having at least three apexes. ~~is expandable from a first, reduced diameter to a second, enlarged diameter.~~

16. (Currently Amended) The prosthesis as in Claim 14, comprising wherein ~~the at least one frond includes at least three fronds.~~

17. (Currently Amended) The prosthesis as in Claim 14, wherein ~~the~~ at least one frond comprises a helical configuration.

18. **(Original)** The prosthesis as in Claim 17, comprising a plurality of helical fronds.

19. **(Currently Amended)** The prosthesis as in Claim 14, wherein at least a portion of the fronds comprises a lubricous coating.

20. **(Currently Amended)** The prosthesis as in Claim 14, wherein ~~the support is on a first end of the fronds, and the circumferential link is on a second end of the frond~~ have an axial length of at least about 8 mm.

21. **(Original)** The prosthesis as in Claim 14, wherein the circumferential link is radiopaque.

22. **(Currently Amended)** The prosthesis as in Claim 21, wherein the circumferential link has a greater radiopacity than the fronds.

23. **(Original)** The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

24. **(Original)** The prosthesis as in Claim 14, comprising a non thrombogenic surface.

25.-29. **(Cancelled)**

30.-35. **(Cancelled)**

36. **(Currently Amended)** The prosthesis as in Claim 14, wherein ~~the at least one frond~~ comprises a plurality of parallel, undulating filaments. ~~fronds and wherein the circumferential link connects to each of the plurality of fronds.~~

37. **(Previously Presented)** The prosthesis as in Claim 36, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug

release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(Currently Amended)** The prosthesis as in Claim 37, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, and anti inflammatory drug.

40. **(Currently Amended)** The prosthesis as in Claim 37, wherein the drug is configured to reduce ~~an incidence or amount of~~ restenosis.

41. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(Previously Presented)** The prosthesis as in Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(Currently Amended)** The prosthesis as in Claim ~~[[36]]~~ 14, wherein the circumferential link comprises a single transverse filament. ~~is expandable from a first, reduced diameter to a second, enlarged diameter.~~

44. **(Currently Amended)** The prosthesis as in Claim ~~[[36]]~~ 14, further comprising a transition section between ~~wherein the support is on a first end of at least one of and the fronds. and the circumferential link is on a second end of at least one of the fronds.~~

45.-46. **(Cancelled)**

47. **(Previously Presented)** The prosthesis of Claim 14, wherein the prosthesis includes a drug incorporated into a polymer matrix.

48. **(Cancelled)**

49. **(Currently Amended)** The prosthesis of Claim ~~48~~ 47, wherein the ~~laminate structure~~ polymer matrix includes a base layer and a top layer, the drug being incorporated into at least one of the top layer and the base layer.

Application No.: 10/584,968
Filing Date: June 30, 2006

50. **(Previously Presented)** The prosthesis of Claim 14, wherein the prosthesis includes one or more reservoirs configured to be loaded with a drug.

51. **(Previously Presented)** The prosthesis of Claim 50, wherein the prosthesis includes one or more drugs in the one or more reservoirs.